The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF- α Expression in Macrophages
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are an effective treatment approach for type 2 diabetes. Recently, anti-inflammatory effects of GLP-1 receptor agonists have also been reported. Lipopolysaccharide (LPS) induces inflammation and osteoclast formation. In this study, we investigated the effect of exendin-4, a widely used GLP-1 receptor agonist, in LPS-induced osteoclast formation and bone resorption. LPS with or without exendin-4 was administered on mouse calvariae by daily subcutaneous injection. The number of osteoclasts, the ratio of bone resorption pits, and the level of C-terminal cross-linked telopeptide of type I collagen (CTX) were significantly lower in LPS- and exendin-4-coadministered mice than in mice administered with LPS alone. RANKL and TNF- α mRNA expression levels were lower in the exendin-4- and LPS-coadministered group than in the LPS-administered group. Our in vitro results showed no direct effects of exendin-4 on RANKL-induced osteoclast formation, TNF- α -induced osteoclast formation, or LPS-induced RANKL expression in stromal cells. Conversely, TNF- α mRNA expression was inhibited in the exendin-4- and LPS-cotreated macrophages compared with cells treated with LPS alone. These results indicate that the GLP-1 receptor agonist exendin-4 may inhibit LPS-induced osteoclast formation and bone resorption by inhibiting LPS-induced TNF- α production in macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“According to previous reports, exendin-4, a GLP-1RA, has the potential to inhibit LPS-induced osteoclast formation and bone resorption in vivo.363,364”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [363]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962 · cited 2×
“Osteoclasts derived from bone marrow cells are responsible for bone resorption and remodeling [10].”
BackgroundThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.275 · Cited by 1,304
Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts
Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., & Kudo, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.4858 · Cited by 731
Osteoclasts: What Do They Do and How Do They Do It?
Teitelbaum, S. L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060834 · Cited by 730 · cited 1×
“Receptor activator of NF-kB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) are two key factors required for osteoclast formation and activation [11].”
BackgroundAssociation of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes
Schwartz, A. V. (2011) · JAMA · doi:10.1001/jama.2011.715 · Cited by 717
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2005) · Diabetologia · doi:10.1007/s00125-005-1786-3 · Cited by 557
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Osteoclasts are essential for TNF-α–mediated joint destruction
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15582 · Cited by 531
Osteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Fuller, K., Murphy, C., Kirstein, B., Fox, S. W., & Chambers, T. J. (2002) · Endocrinology · doi:10.1210/endo.143.3.8701 · Cited by 335
Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334
The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
M-CSF mediates TNF-induced inflammatory osteolysis
Kitaura, H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26132 · Cited by 292
Self-citationAbu-Amer, Y., Ross, F. P., Edwards, J., & Teitelbaum, S. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119679 · Cited by 289
Kikuchi, T., Matsuguchi, T., Tsuboi, N., Mitani, A., Tanaka, S., Matsuoka, M., Yamamoto, G., Hishikawa, T., Noguchi, T., & Yoshikai, Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3574 · Cited by 255
Obesity, Type 2 Diabetes and Bone in Adults
Walsh, J. S., & Vilaca, T. (2017) · Calcified Tissue International · doi:10.1007/s00223-016-0229-0 · Cited by 245
Dual Modulation of Osteoclast Differentiation by Lipopolysaccharide
Zou, W., & Bar-Shavit, Z. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1211 · Cited by 219
Moayeri, A., Mohamadpour, M., Mousavi, S., Shirzadpour, E., Mohamadpour, S., & Amraei, M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s131945 · Cited by 219
Garlet, G. P., Cardoso, C. R., Silva, T. A., Ferreira, B. R., Ávila‐Campos, M. J., Cunha, F. Q., & Silva, J. S. (2006) · Oral Microbiology and Immunology · doi:10.1111/j.1399-302x.2005.00245.x · Cited by 201
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Nuche-Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro-Mora, J. J., & Villanueva-Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192
Kitaura, H., Sands, M. S., Aya, K., Zhou, P., Hirayama, T., Uthgenannt, B., Wei, S., Takeshita, S., Novack, D. V., Silva, M. J., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4838 · Cited by 190
Self-citationChiang, C.-Y., Kyritsis, G., Graves, D. T., & Amar, S. (1999) · Infection and Immunity · doi:10.1128/iai.67.8.4231-4236.1999 · Cited by 178
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178 · cited 1×
“However, a recent meta-analysis has reported that GLP-1 receptor agonist treatment does not affect fracture risk in type 2 diabetic patients [36, 37].”
BackgroundKitaura, H., Kimura, K., Ishida, M., Kohara, H., Yoshimatsu, M., & Takano-Yamamoto, T. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/181849 · Cited by 176
Self-citationWada, N., Maeda, H., Yoshimine, Y., & Akamine, A. (2004) · Bone · doi:10.1016/j.bone.2004.04.023 · Cited by 163
Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
Nuche‐Berenguer, B., Moreno, P., Portal‐Núñez, S., Dapía, S., Esbrit, P., & Villanueva‐Peñacarrillo, M. L. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.06.010 · Cited by 149
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01225.x · Cited by 135
Dumitrescu, A. L., Abd El‐Aleem, S., Morales‐Aza, B., & Donaldson, L. F. (2004) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2004.00528.x · Cited by 132
Sakuma, Y., Tanaka, K., Suda, M., Yasoda, A., Natsui, K., Tanaka, I., Ushikubi, F., Narumiya, S., Segi, E., Sugimoto, Y., et al. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.2.218 · Cited by 121
Mörmann, M., Thederan, M., Nackchbandi, I., Giese, T., Wagner, C., & Hänsch, G. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.04.022 · Cited by 100
Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M., Northcutt, A. R., Kravitz, B. G., Paul, G., Cobitz, A. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4018 · Cited by 99
Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.
Nielsen, L. L., & Baron, A. (2003) · PubMed · Cited by 82
Antidiabetic therapy effects on bone metabolism and fracture risk
Montagnani, A., & Gonnelli, S. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12077 · Cited by 80
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
Betteridge, D. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03187.x · Cited by 79
Orcel, P., Feuga, M., Bielakoff, J., & de Vernejoul, M. C. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.3.e391 · Cited by 77
Bostancı, N., Allaker, R. P., Belibasakis, G. N., Rangarajan, M., Curtis, M. A., Hughes, F. J., & McKay, I. J. (2007) · Cytokine · doi:10.1016/j.cyto.2007.07.002 · Cited by 71
Chung, Y., Chang, E.-J., Kim, S. ‐., Kim, H. ‐., Kim, H. ‐., Lee, S., & Ko, J.-H. (2006) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00876.x · Cited by 49
Incretin-based therapies: mimetics versus protease inhibitors
Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 48
IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
Saeed, J., Kitaura, H., Kimura, K., Ishida, M., Sugisawa, H., Ochi, Y., Kishikawa, A., & Takano‐Yamamoto, T. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.04.004 · Cited by 39
Self-citationAnti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo
Kimura, K., Kitaura, H., Fujii, T., Hakami, Z. W., & Takano‐Yamamoto, T. (2011) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2011.00888.x · Cited by 31
Self-citationUse of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
Bazelier, M. T., Gallagher, A. M., van Staa, T., Cooper, C., Leufkens, H. G. M., Vestergaard, P., & de Vries, F. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3234 · Cited by 29
Risk of Fracture with Thiazolidinediones: Disease or Drugs?
Bazelier, M. T., Vestergaard, P., Gallagher, A. M., van Staa, T.-P., Cooper, C., Leufkens, H. G. M., & de Vries, F. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9591-8 · Cited by 28
Ma, X., Hui, H., Liu, Z., He, G., Hu, J. R., Meng, J., Guan, L., & Luo, X. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01070.x · Cited by 18
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
The role of GPCRs in bone diseases and dysfunctions
Luo, J., Sun, P., Siwko, S., Liu, M., & Xiao, J. (2019) · Bone Research · doi:10.1038/s41413-019-0059-6 · Cited by 99
Ghosh, S., Luo, D., He, W., Chen, J., Su, X., & Huang, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104861 · Cited by 102
Wei, M., Li, C., Dai, Y., Zhou, H., Cui, Y., Zeng, Y., Huang, Q., & Wang, Q. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.630372 · Cited by 99
“Lipopolysaccharide (LPS), a component of the gram-negative bacterial outer membrane, can stimulate the production of pro-inflammatory cytokines, resulting in systemic inflammations (Maldonado et al., 2016; Shen et al., 2018).”
BackgroundCai, T.-T., Li, H.-Q., Jiang, L.-L., Wang, H.-Y., Luo, M.-H., Su, X.-F., & Ma, J.-H. (2021) · BioMed Research International · doi:10.1155/2021/3361309 · Cited by 84
“GLP-1 RAs can also reduce the number of osteoclasts and levels of serum bone resorption markers along with inhibiting bone resorption [26, 29].”
Background
Metadata
- Authors
- Shen, W.-R., Kimura, K., Ishida, M., Sugisawa, H., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., & Kitaura, H.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Kitaura, Hideki
- ORCID
- Kitaura, Hideki
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Issue
- 5783639
- Pages
- 1-10
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC5872659
- OpenAlex
- W2789846563
- Cited by
- 45
- References
- 46
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 8 · 2019: 7
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (16K11776)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- exendin-4, GLP-1 receptor agonists, osteoclastogenesis, bone resorption, lipopolysaccharide, TNF-α, macrophages, RANKL, anti-inflammatory activity, type 2 diabetes, calvaria, CTX
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anti-Inflammatory Agents, Bone Resorption, Cell Differentiation, Cells, Cultured, Diabetes Mellitus, Type 2, Lipopolysaccharides, Macrophages, Male, Mice, Inbred C57BL, Osteoclasts, Peptides, Tumor Necrosis Factor-alpha, Venoms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.